Closing in on HIV goals

The latest World AIDS Day report from UNAIDS is boldly entitled Results, presumably representing an optimistic recognition that tangible and extensive progress is being made. As is pointed out in the foreword by Aung San Suu Kyi and Michel Sidibé in reference to access to treatment, “what had taken a decade before is now being achieved in 24 months”. But in addition to optimism, the report is an attempt to sustain momentum as we enter the “final years of working towards the [2015] Millennium Development Goals and the United Nations Political Declaration on HIV/AIDS”.

The headline statistic from the report is a greater than 50% drop in new infections with HIV in 25 low-income and middle-income countries between 2001 and 2011. Most of these countries are in sub-Saharan Africa, where most new infections occur. In total this reduction represents 700,000 fewer new infections worldwide in 2011 than in 2001. South Africa (the country with the highest number of people infected with HIV) is not among these countries, although it has achieved a commendable reduction of 41% during the same period. But it is not universally good news—sub-Saharan Africa still accounted for 72% of all new infections with HIV. There were also substantial increases in the numbers of new infections in many countries of Asia, eastern Europe, and Oceania. However, these more negative data are not overlooked in the report; it is acknowledged that this is not a time for complacency, and recognised that the road to zero new infections is a long one.

AIDS-related deaths have also decreased substantially. This success is attributed to “sustained investments in access to antiretroviral therapy by donors and national governments”. But the gap between the need for treatment and access is still 46%, and an earlier report from UNAIDS, Meeting the Investment Challenge, stated that at present rates of investment there would be an estimated investment gap greater than US$7 billion by 2015. A substantial proportion (48%) of present funding comes from the USA, so its renewed commitment in the form of the PEPFAR Blueprint provides some reassurance.

Although funding overall seems good ($16·8 billion at present with an estimated $24 billion needed by 2015), breakdown of the distribution of funding reveals that resources need to be more strategically targeted at key risk groups and key interventions. For example, the prevention of mother-to-child transmission receives $201 million, but $1·1 billion will be needed by 2015. Similarly, investments aimed at effecting behavioural change have received $70 million, substantially less than the estimated $625 million needed.

The targeting of mother-to-child transmission is crucial, particularly because good progress has been made: between 2009 and 2011, half of all new infections with HIV averted were in newborns. It is essential that this momentum is not lost. As the report states, “more effort is needed to ensure that pregnant women tested for HIV during antenatal care are also tested for eligibility for antiretroviral therapy”. In addition to maintaining efforts in sub-Saharan Africa where progress has been made, we also need to ensure that such interventions in other regions are brought up to more acceptable levels. Coverage in south and southeast Asia is 18% and in the Middle East and north Africa is 7%. Overall, only 30% of eligible pregnant women with HIV received antiretroviral therapy in 2011.

The report calls for qualitative research to establish why pregnant women are not starting treatment despite improvements in access to health care.

Continuing the focused approach to tackling HIV, the populations at highest risk need to be more effectively targeted. Sex workers, men who have sex with men, and injecting drug users are still disproportionately affected by HIV. The poor responses to these groups continues to be the greatest failure in the tackling of HIV/AIDS. The inevitably political reasons behind these failures call into question some of the commitment to genuinely see the back of the disease.

As with many recent reports on HIV, the message is that much has been achieved but there is still much to be done. However, although we must not lose sight of our 2015 target we must also begin to take a longer view and ask ourselves if the political will to tackle HIV will continue beyond this watershed. As we push towards the goals of 2015 we must ensure that the results are tangible and sustained. Nothing would make a greater mockery of the efforts so far than triumphant headlines come 2015, but with waning commitments when the spotlight fades. ■ The Lancet Infectious Diseases